BRD4 inhibition with JQ1 disrupted immunosuppressive gene activation, and its combination with EGFR CAR-T therapy reduced immunosuppression, effectively curbing tumor growth and metastasis in GBM xenografts [158]. Here, EGFR is linked to neoplasm.